HEMOGENYX PHARMACEUTICALS PLC

Director's Dealing • Aug 21, 2020

National Storage Mechanism | Additional information

RNS Number : 8331W

Hemogenyx Pharmaceuticals PLC

21 August 2020

21 August 2020

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

Grant of Options

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company ("Share Options") to the Company's co-founder and CEO Dr Vladislav Sandler.

The details of the Share Options granted are set out below:

Name	Position	Number of Share Options Granted	Exercise Price (pence)	Vesting Date	Expiry Date
Dr Vladislav Sandler	CEO	5,000,000	7	Immediate	19 August 2025

Following the grant of the Share Options there are, in aggregate, 42,465,786 ordinary shares of 1p each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company, representing 9.79% of the issued ordinary share capital of the Company.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

1.

Details of PDMR/person closely associated with them

a)

Name

Dr Vladislav Sandler

b)

Position/status

CEO, Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc

Identification code GB00BYX3WZ24

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£0.07	5,000,000

d)

Aggregated information

-     Aggregated volume

-     Price

Price(s)	Volume(s)
N/A - variable	5,000,000

e)

Date of the transaction

20/08/2020

f)

Place of the transaction

Outside of a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHDZGZRRMRGGZG